• Company unaware of any price-sensitive information not yet announced
• Received $300k purchase order for HIV test kits, not considered material
• Confirmed compliance with continuous disclosure obligations

Atomo Diagnostics Limited (ASX: AT1) responded to an ASX price query regarding the recent trading in its securities. The company stated that it is not aware of any price-sensitive information that has not been announced to the market, which could explain the recent trading. The company recently received a purchase order for the supply of 65,000 HIV Self Test Kits destined for Ukraine and funded by USAID. However, the estimated revenue from this purchase order was below the company's materiality threshold of $300,000, and hence it was not considered material information that required an ASX announcement. The company communicated the receipt of this purchase order through its investor relations channels. Atomo Diagnostics confirmed that it is in compliance with the disclosure provisions of the Listing Rules, particularly Listing Rule 3.1.